Lawrence Fox

4.3k total citations
41 papers, 1.8k citations indexed

About

Lawrence Fox is a scholar working on Virology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Lawrence Fox has authored 41 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Virology, 26 papers in Infectious Diseases and 15 papers in Epidemiology. Recurrent topics in Lawrence Fox's work include HIV Research and Treatment (33 papers), HIV/AIDS Research and Interventions (18 papers) and HIV/AIDS drug development and treatment (18 papers). Lawrence Fox is often cited by papers focused on HIV Research and Treatment (33 papers), HIV/AIDS Research and Interventions (18 papers) and HIV/AIDS drug development and treatment (18 papers). Lawrence Fox collaborates with scholars based in United States, United Kingdom and France. Lawrence Fox's co-authors include Alan Landay, Michael M. Lederman, John Spritzler, Harold A. Kessler, Daniel R. Kuritzkes, Elizabeth Connick, Hernán Valdez, Ronald J. Bosch, Marty St. Clair and Richard B. Pollard and has published in prestigious journals such as Blood, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Lawrence Fox

41 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lawrence Fox United States	22	1.2k	919	589	532	285	41	1.8k
P T Schellekens Netherlands	23	1.8k 1.5×	1.2k 1.3×	1.1k 1.9×	683 1.3×	209 0.7×	52	2.7k
Emmanouil Papasavvas United States	22	987 0.8×	528 0.6×	870 1.5×	318 0.6×	162 0.6×	46	1.7k
J Aboulker France	23	1.1k 0.9×	1.1k 1.2×	254 0.4×	435 0.8×	338 1.2×	91	1.8k
Robert Yarchoan United States	16	787 0.7×	833 0.9×	260 0.4×	428 0.8×	104 0.4×	20	1.4k
Marina Karmochkine France	22	737 0.6×	696 0.8×	401 0.7×	414 0.8×	113 0.4×	70	1.7k
Evgenia Aga United States	16	1.2k 1.0×	983 1.1×	451 0.8×	262 0.5×	179 0.6×	32	1.5k
Christina M. Lalama United States	17	862 0.7×	765 0.8×	188 0.3×	178 0.3×	194 0.7×	36	1.2k
Moti Ramgopal United States	21	901 0.8×	1.1k 1.2×	250 0.4×	418 0.8×	322 1.1×	83	1.5k
Miguel Genebat Spain	19	552 0.5×	376 0.4×	331 0.6×	263 0.5×	210 0.7×	55	902
Anne Krivine France	20	404 0.3×	617 0.7×	201 0.3×	484 0.9×	124 0.4×	42	1.1k

Countries citing papers authored by Lawrence Fox

Since Specialization

Citations

This map shows the geographic impact of Lawrence Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence Fox more than expected).

Fields of papers citing papers by Lawrence Fox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence Fox. The network helps show where Lawrence Fox may publish in the future.

Co-authorship network of co-authors of Lawrence Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence Fox. A scholar is included among the top collaborators of Lawrence Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence Fox. Lawrence Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dubé, Karine, Lawrence Fox, Lynda Dee, et al.. (2023). A partner protection package for HIV cure-related trials involving analytical treatment interruptions. The Lancet Infectious Diseases. 23(10). e418–e430. 13 indexed citations

Diepstra, Karen, Elizabeth Barr, David Palm, et al.. (2021). Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study. AIDS Research and Human Retroviruses. 37(6). 489–501. 8 indexed citations

Cillo, Anthony R., Christina M. Lalama, John E. McKinnon, et al.. (2015). Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery. AIDS. 29(16). 2121–2129. 21 indexed citations

Bosch, Ronald J., Richard B. Pollard, Alan Landay, Evgenia Aga, & Lawrence Fox. (2011). A Randomized Trial of Interleukin-2 During Withdrawal of Antiretroviral Treatment. Journal of Interferon & Cytokine Research. 31(6). 481–483. 4 indexed citations

Firnhaber, Cynthia, Livio Azzoni, Andrea S. Foulkes, et al.. (2011). Randomized Trial of Time-Limited Interruptions of Protease Inhibitor-Based Antiretroviral Therapy (ART) vs. Continuous Therapy for HIV-1 Infection. PLoS ONE. 6(6). e21450–e21450. 8 indexed citations

Gandhi, Rajesh T., David O’Neill, Ronald J. Bosch, et al.. (2009). A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine. 27(43). 6088–6094. 67 indexed citations

Twigg, Homer L., Michael D. Weiden, Fred Valentine, et al.. (2007). Effect of Highly Active Antiretroviral Therapy on Viral Burden in the Lungs of HIV‐Infected Subjects. The Journal of Infectious Diseases. 197(1). 109–116. 40 indexed citations

Kilby, J Michael, R. Pat Bucy, Donna Mildvan, et al.. (2006). A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV‐Specific Immunizations, and Interleukin‐2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024). The Journal of Infectious Diseases. 194(12). 1672–1676. 60 indexed citations

Frank, Ian, Ronald J. Bosch, Susan A. Fiscus, et al.. (2004). Activity, Safety, and Immunological Effects of Hydroxyurea Added to Didanosine in Antiretroviral-Naive and Experienced HIV Type 1-Infected Subjects: A Randomized, Placebo-Controlled Trial, ACTG 307. AIDS Research and Human Retroviruses. 20(9). 916–926. 21 indexed citations

10.

Valdez, Hernán, Ronald T. Mitsuyasu, Alan Landay, et al.. (2003). Interleukin‐2 Increases CD4⁺Lymphocyte Numbers but Does Not Enhance Responses to Immunization: Results of A5046s. The Journal of Infectious Diseases. 187(2). 320–325. 43 indexed citations

11.

Wallis, Robert S., Robert C. Kalayjian, Jeffrey M. Jacobson, et al.. (2003). A Study of the Immunology, Virology, and Safety of Prednisone in HIV-1–Infected Subjects with CD4 Cell Counts of 200 to 700 mm−3. JAIDS Journal of Acquired Immune Deficiency Syndromes. 32(3). 281–286. 39 indexed citations

12.

Kalayjian, Robert C., Alan Landay, Richard B. Pollard, et al.. (2003). Age‐Related Immune Dysfunction in Health and in Human Immunodeficiency Virus (HIV) Disease: Association of Age and HIV Infection with Naive CD8⁺Cell Depletion, Reduced Expression of CD28 on CD8⁺Cells, and Reduced Thymic Volumes. The Journal of Infectious Diseases. 187(12). 1924–1933. 121 indexed citations

13.

Jacobson, Jeffrey M., Michael M. Lederman, John Spritzler, et al.. (2003). Granulocyte‐Macrophage Colony‐Stimulating Factor Induces Modest Increases in Plasma Human Immunodeficiency Virus (HIV) Type 1 RNA Levels and CD4⁺Lymphocyte Counts in Patients with Uncontrolled HIV Infection. The Journal of Infectious Diseases. 188(12). 1804–1814. 14 indexed citations

14.

Pollard, Richard B., Camlin Tierney, Diane V. Havlir, et al.. (2002). A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine versus Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naive (ACTG 298). AIDS Research and Human Retroviruses. 18(10). 699–704. 7 indexed citations

15.

Sha, Beverly E., Hernán Valdez, Rebecca Gelman, et al.. (2002). Short Communication : Effect of Etanercept (Enbrel) on Interleukin 6, Tumor Necrosis Factor α , and Markers of Immune Activation in HIV-Infected Subjects Receiving Interleukin 2. AIDS Research and Human Retroviruses. 18(9). 661–665. 39 indexed citations

16.

Wohl, David A., Francesca Aweeka, John L. Schmitz, et al.. (2002). Safety, Tolerability, and Pharmacokinetic Effects of Thalidomide in Patients Infected with Human Immunodeficiency Virus: AIDS Clinical Trials Group 267. The Journal of Infectious Diseases. 185(9). 1359–1363. 12 indexed citations

17.

Valdez, Hernán, Elizabeth Connick, Kimberly Y. Smith, et al.. (2002). Limited immune restoration after 3 years’ suppression of HIV-1 replication in patients with moderately advanced disease. AIDS. 16(14). 1859–1866. 179 indexed citations

18.

Jacobson, Jeffrey M., John S. Greenspan, John Spritzler, et al.. (2001). Thalidomide in Low Intermittent Doses Does Not Prevent Recurrence of Human Immunodeficiency Virus–Associated Aphthous Ulcers. The Journal of Infectious Diseases. 183(2). 343–346. 17 indexed citations

19.

Havlir, Diane V., Camlin Tierney, Gerald Friedland, et al.. (2000). In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy. The Journal of Infectious Diseases. 182(1). 321–325. 59 indexed citations

20.

Kvamme, Peter, et al.. (1992). Comparative effects of endothelin (ET-1) and U46619 on human saphenous vein and gastroepiploic artery, sources of human autologous grafts. Molecular and Cellular Biochemistry. 117(1). 81–5. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact